Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA

Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, announced that it has started clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (NSCLC). Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial that combines Genprex’s lead drug candidate, REQORSA immunogene therapy, with Merck & Co’s Keytruda in patients with “late-stage NSCLC who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (PD-L1),” said the company. The TUSC2 gene is a tumor suppressor gene and is the active agent in REQORSA.  READ: Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting “Our clinical team remains focused on engaging with leading clinical investigators and esteemed research institutions in order to further our mission of bringing hope to lung cancer patients who are in need of new treatment options,” Genprex CEO Rodney Varner said in a statement. “We look forward to selecting the most optimal study sites, which will help to further fuel the success of our clinical trials,” he added. The Austin, Texas-based company plans to conduct the Acclaim-2 clinical trial in approximately 15 sites with about 150 patients in an adaptive Phase 1/2 design. The final protocol is subject to change based on input from investigators, noted the company. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive

Post a Comment